- Teleflex Incorporated (NYSE: TFX) reported Q2 FY22 revenues of $704.5 million, down 1.3% Y/Y, up 2.3% on a constant currency basis, missing the consensus of $719.50 million.
- Lower sales from the Interventional Urology segment impacted the revenue. The company did not see the expected operating environment recovery in the Interventional Urology business during the second quarter.
- Adjusted diluted EPS increased 1.2% to $3.39, exceeding the consensus of $3.34.
- The gross margin remained flat at 59%.
- FY22 Guidance: Teleflex cut GAAP and constant currency revenue growth guidance to (0.45)% to 0.55% and 3.25% to 4.25%, respectively.
- The company lowered adjusted EPS to $13.00 - $13.40 from $13.70 - $14.30, below the consensus of $13.97.
- Price Action: TFX shares are down 6.53% at $249.13 during the market session on the last check Thursday.
Read at Benzinga